Browse five skin and anti-aging peptides tracked on Peptigrity, with verified third-party HPLC purity data, shop coverage, and mechanism research for each. The category covers three mechanism classes: copper-binding peptides for collagen synthesis and hair (GHK-Cu, AHK-Cu), melanocortin receptor agonists for pigmentation (Melanotan I, Melanotan II), and SNARE complex modulators for topical wrinkle reduction (SNAP-8). Routes of administration vary significantly across this category - some are injection-only, others are formulated for topical use.
Last updated: April 2026
Skin and anti-aging peptides target very different biology - pigmentation, collagen synthesis, or wrinkle-causing muscle contraction - through distinct mechanisms. Choose by the specific cosmetic outcome being researched, not by general "anti-aging" framing.
Copper peptides exploit a coincidence of biology: copper is a cofactor for several enzymes critical to collagen and elastin synthesis (lysyl oxidase chief among them), and certain short peptides bind copper with just the right affinity to deliver it to those enzymes selectively. GHK-Cu's three amino acids form a copper-binding pocket; the resulting complex is stable enough to circulate but labile enough to release copper at tissue sites. The downstream effects - collagen synthesis, elastin remodeling, antioxidant gene expression, wound healing acceleration - are documented across decades of preclinical and cosmetic-grade clinical research.
Melanocortin receptor agonists work through a different mechanism entirely. Endogenous alpha-MSH (alpha-melanocyte-stimulating hormone) binds MC1R on melanocytes, triggering eumelanin synthesis - the dark brown pigment that provides UV photoprotection. Melanotan I is a cyclic alpha-MSH analog with greater receptor stability than the natural peptide. Melanotan II adds activity at MC4R (appetite, sexual function) and MC3R (energy homeostasis), which is why it produces effects beyond pigmentation. The MC1R activation pathway is the same; the receptor selectivity differs.
SNAP-8 targets the SNARE complex, the molecular machinery that releases neurotransmitters at synapses. Botulinum toxin works by cleaving SNAP-25, one of three SNARE proteins. SNAP-8 takes a non-toxic approach: it competes with native SNAP-25 for inclusion in the SNARE complex, producing the same downstream effect (reduced neurotransmitter release) through competition rather than enzymatic cleavage. This makes it topical-safe but considerably weaker than botulinum injections - the research-reported effect sizes are smaller and require sustained topical application rather than periodic injection.
For deeper background on peptide manufacturing and verification, see how peptides are made.
This category has a unique verification dimension: cosmetic-grade vs research-grade.
COSMETIC-GRADE FORMULATIONS: GHK-Cu, AHK-Cu, and SNAP-8 are widely sold in regulated skincare at cosmetic concentrations. These formulations are generally produced under cosmetics-industry quality standards and are appropriate for topical use. Verifying these products is a different exercise - checking ingredient lists, brand reputation, and concentration claims - than verifying research peptides.
RESEARCH-GRADE INJECTABLE: The same compounds are also sold as research peptides for injection at higher concentrations. These should meet the same HPLC purity (≥98%) and mass spectrometry identity standards as any research peptide. Buyers crossing from cosmetic skincare to research peptide should not assume regulatory protection transfers - research peptide purity is verified through independent third-party testing.
MELANOTAN COPPER-COMPLEX CONFUSION: Melanotan compounds sometimes ship as sodium-salt or with copper-binding modifications added by sellers. Verify the form being shipped via mass spectrometry, particularly when buying from low-volume vendors.
None of the 5 compounds in this category are FDA-approved. Melanotan I (afamelanotide) is approved in the European Union as Scenesse for erythropoietic protoporphyria, but does not have FDA approval in the United States. The other four compounds are research peptides or cosmetic ingredients without specific FDA drug approval. Cosmetic-grade formulations of GHK-Cu, AHK-Cu, and SNAP-8 are regulated under cosmetics law rather than drug law, which is a different regulatory framework with different requirements.
→ Country-specific peptide regulatory status: /blog/are-peptides-legal-regulatory-status-by-country
None of the 5 compounds in this category are FDA-approved. Melanotan I (afamelanotide) is approved in the European Union as Scenesse for erythropoietic protoporphyria, but does not have FDA approval in the United States. The other four compounds are research peptides or cosmetic ingredients without specific FDA drug approval. Cosmetic-grade formulations of GHK-Cu, AHK-Cu, and SNAP-8 are regulated under cosmetics law rather than drug law, which is a different regulatory framework with different requirements.
→ Country-specific peptide regulatory status: /blog/are-peptides-legal-regulatory-status-by-country
The two routes serve different research goals. Topical GHK-Cu is the predominant cosmetic use case, supported by clinical research on skin appearance, fine line reduction, and hair density. Injection-based GHK-Cu research has investigated systemic effects on wound healing and tissue regeneration that are difficult to achieve through topical absorption alone. The injection route requires research-peptide-grade material and appropriate verification; the topical route can use cosmetic-grade formulations at lower concentrations. They are not substitutes for one another.
→ GHK-Cu dosage and protocol guide (covers both routes): /blog/ghk-cu-dosage-protocol-guide-injection-topical-stacking
The two routes serve different research goals. Topical GHK-Cu is the predominant cosmetic use case, supported by clinical research on skin appearance, fine line reduction, and hair density. Injection-based GHK-Cu research has investigated systemic effects on wound healing and tissue regeneration that are difficult to achieve through topical absorption alone. The injection route requires research-peptide-grade material and appropriate verification; the topical route can use cosmetic-grade formulations at lower concentrations. They are not substitutes for one another.
→ GHK-Cu dosage and protocol guide (covers both routes): /blog/ghk-cu-dosage-protocol-guide-injection-topical-stacking
Receptor selectivity. Melanotan I is selective for MC1R, the melanocortin receptor on melanocytes responsible for eumelanin production. Effects are limited to pigmentation. Melanotan II also activates MC4R (appetite, sexual function) and MC3R (energy homeostasis), producing broader effects beyond pigmentation - including the libido and appetite changes the compound is informally known for. MT-2's broader receptor profile also produces more side effects. MT-1 has EU regulatory approval for a specific indication; MT-2 has no regulatory approval anywhere.
Receptor selectivity. Melanotan I is selective for MC1R, the melanocortin receptor on melanocytes responsible for eumelanin production. Effects are limited to pigmentation. Melanotan II also activates MC4R (appetite, sexual function) and MC3R (energy homeostasis), producing broader effects beyond pigmentation - including the libido and appetite changes the compound is informally known for. MT-2's broader receptor profile also produces more side effects. MT-1 has EU regulatory approval for a specific indication; MT-2 has no regulatory approval anywhere.
No, with qualification. SNAP-8 acts on the same downstream molecular target (the SNARE complex) as botulinum toxin, but the magnitude of effect is dramatically smaller. Cosmetic clinical research has reported wrinkle depth reductions in the 25-30% range with sustained topical application, versus 80%+ reductions typical of botulinum injections. SNAP-8 is best understood as a topical adjunct or alternative for users who specifically want to avoid injections, not as a like-for-like substitute. The mechanism is similar; the outcome is not.
No, with qualification. SNAP-8 acts on the same downstream molecular target (the SNARE complex) as botulinum toxin, but the magnitude of effect is dramatically smaller. Cosmetic clinical research has reported wrinkle depth reductions in the 25-30% range with sustained topical application, versus 80%+ reductions typical of botulinum injections. SNAP-8 is best understood as a topical adjunct or alternative for users who specifically want to avoid injections, not as a like-for-like substitute. The mechanism is similar; the outcome is not.
Skin and hair research protocols use different concentrations and sometimes different administration routes. Skin protocols typically use topical formulations at 0.1-2% concentration, often layered into existing skincare. Hair protocols include scalp-applied topicals and, in some research contexts, mesotherapy injection. The GHK-Cu calculator handles the math for both routes. AHK-Cu is also worth considering for hair-specific research given its targeted mechanism.
→ GHK-Cu calculator: /tools/ghk-cu-calculator
→ GHK-Cu protocol guide (skin and hair): /blog/ghk-cu-dosage-protocol-guide-injection-topical-stacking
→ AHK-Cu profile: /peptides/ahk-cu
Skin and hair research protocols use different concentrations and sometimes different administration routes. Skin protocols typically use topical formulations at 0.1-2% concentration, often layered into existing skincare. Hair protocols include scalp-applied topicals and, in some research contexts, mesotherapy injection. The GHK-Cu calculator handles the math for both routes. AHK-Cu is also worth considering for hair-specific research given its targeted mechanism.
→ GHK-Cu calculator: /tools/ghk-cu-calculator
→ GHK-Cu protocol guide (skin and hair): /blog/ghk-cu-dosage-protocol-guide-injection-topical-stacking
→ AHK-Cu profile: /peptides/ahk-cu